Oncology Animated Video 

BRAF V600E mutated NSCLC: The evolving treatment landscape

Expert insights into personalised treatment strategies in BRAF-mutated NSCLC

Prof. Amanda Tufman

Prof. Amanda Tufman
Publication Date

May 2025

info Summary and next episodes download Downloadable resources

In this short, animated video, lung cancer expert Prof. Amanda Tufman provides an overview of the clinical trial data and emerging profile of therapies for the treatment of BRAFV600E mutated non-small cell lung cancer (NSCLC).


Prof. Tufman then moves on to highlight her views on the appropriate placement of therapies across the patient journey in the evolving treatment landscape.

 

The video is accompanied by a helpful slide set which provides more detail behind the key points addressed by Prof. Tufman. Find your slide set as a downloadable resource on this page.

 

Clinical takeaways

  • BRAFV600E is an actionable mutation for metastatic NSCLC with effective and well-tolerated treatment options available
  • The BRAF mutation should be tested for at the time of first diagnosis for all patients with advanced NSCLC
  • Only around half of patients with metastatic NSCLC receive a second-line treatment, so the most appropriate, efficacious treatments should be used in the first-line setting
  • BRAF-targeted treatment combinations are approved for first-line treatment of NSCLC
  • Understand the clinical trial data and emerging profile (efficacy and potential toxicities) of therapies for the treatment of BRAFV600E mutated NSCLC
  • Recognise the appropriate placement of therapies for the treatment of BRAFV600E mutated NSCLC across the patient journey

Professor Amanda Tufman is a thoracic oncologist specialising in understanding the molecular mechanisms underlying thoracic cancers and developing innovative therapeutic strategies.

 

Professor Tufman’s clinical work includes cutting-edge research into the molecular biology of lung cancer.  Her work involves developing targeted therapies and personalised medicine strategies aimed at improving the prognosis for patients with lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Her research focuses on the genetic mutations that drive these cancers and the ways in which targeted therapies can address specific vulnerabilities in cancer cells.

 

Professor Tufman has also been at the forefront of improving early detection methods for lung cancer, emphasizing the importance of early intervention in improving survival rates. Her work in this area has led to advancements in imaging techniques, biomarkers, and screening programs that aid in identifying lung cancer at an earlier and more treatable stage.

 

In addition to her clinical and academic roles, Professor Tufman is an active member of numerous international oncology societies. She has served on editorial boards for several medical journals, contributed to influential publications, and participated in various international conferences and symposia.

Prof. Amanda Tufman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pierre Fabre Laboratoires, Roche, Takeda

 

 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock

In this short, animated video, lung cancer expert Prof. Amanda Tufman provides an overview of the clinical trial data and emerging profile of therapies for the treatment of BRAFV600E mutated non-small cell lung cancer (NSCLC).


Prof. Tufman then moves on to highlight her views on the appropriate placement of therapies across the patient journey in the evolving treatment landscape.

 

The video is accompanied by a helpful slide set which provides more detail behind the key points addressed by Prof. Tufman. Find your slide set as a downloadable resource on this page.

 

Clinical takeaways

  • BRAFV600E is an actionable mutation for metastatic NSCLC with effective and well-tolerated treatment options available
  • The BRAF mutation should be tested for at the time of first diagnosis for all patients with advanced NSCLC
  • Only around half of patients with metastatic NSCLC receive a second-line treatment, so the most appropriate, efficacious treatments should be used in the first-line setting
  • BRAF-targeted treatment combinations are approved for first-line treatment of NSCLC
  • Understand the clinical trial data and emerging profile (efficacy and potential toxicities) of therapies for the treatment of BRAFV600E mutated NSCLC
  • Recognise the appropriate placement of therapies for the treatment of BRAFV600E mutated NSCLC across the patient journey

Professor Amanda Tufman is a thoracic oncologist specialising in understanding the molecular mechanisms underlying thoracic cancers and developing innovative therapeutic strategies.

 

Professor Tufman’s clinical work includes cutting-edge research into the molecular biology of lung cancer.  Her work involves developing targeted therapies and personalised medicine strategies aimed at improving the prognosis for patients with lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Her research focuses on the genetic mutations that drive these cancers and the ways in which targeted therapies can address specific vulnerabilities in cancer cells.

 

Professor Tufman has also been at the forefront of improving early detection methods for lung cancer, emphasizing the importance of early intervention in improving survival rates. Her work in this area has led to advancements in imaging techniques, biomarkers, and screening programs that aid in identifying lung cancer at an earlier and more treatable stage.

 

In addition to her clinical and academic roles, Professor Tufman is an active member of numerous international oncology societies. She has served on editorial boards for several medical journals, contributed to influential publications, and participated in various international conferences and symposia.

Prof. Amanda Tufman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Lilly, MSD, Novartis, Pierre Fabre Laboratoires, Roche, Takeda

 

 
pdf Download slides - PDF clock
pdf Download slides - PPTX clock
Programme summary
Watch the video now
Share this programme
x-twitter
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved
Programme summary
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

LUNG CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Pierre Fabre Laboratories and Boehringer Ingelheim.

Meet the experts
Brought to you by
PRECISION ONCOLOGY CONNECT

PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Amoy Diagnostics, Bayer, Pierre Fabre Laboratories, Thermo Fisher Scientific and Daiichi Sankyo.

Meet the experts Independent IME approved

Other programmes of interest

podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from Daiichi Sankyo 
eks
EKS / On-demand webinar
Oncology 
Multiple Myeloma: Is it time to rethink how we sequence treatments?

On-demand materials from an Experts Knowledge Share event

Experts
Prof. Karthik Ramasamy, Dr Joshua Richter, Dr Faisal Basheer, Dr Andrew Charlton
  • download Downloadable
    Resources
  • clock 80 MIN
  • calendar Mar 2026
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for HCPs in the UK only    MAT-GB-SEL-00774
conference-update Conference update

Episode

2

of 2

episode
Oncology Rare diseases Endocrinology 
Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
Cette vidéo est soutenue par une subvention indépendante à visée éducative d’Ipsen.  Les contenus publiés sur ce site internet sont sous la responsabilité de leurs auteurs. Certaines données scientifiques publiées sur ce site sont susceptibles de ne pas être validées par la commission d’Autorisation de Mise sur le Marché, et ne doivent pas être mises en pratique. Elles doivent être lues et comprises avec le plus grand discernement et sont données dans leur cadre de la diffusion de l’information sur l’état actuel de la recherche auprès de la communauté scientifique internationale  
conference-update Conference update

Episode

1

of 2

episode
Oncology Rare diseases Endocrinology 
Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Experts
Prof. Louis de Mestier, Prof. Timon Vandamme, Dr Alice Durand
  • clock 5 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
NET CONNECT
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
patient-support Patient Support
Oncology Hemato-oncology Pediatrics 
Personalised treatment in childhood cancer: A journey through NTRK fusion testing

Experts
Linet Menachery
Endorsed by
NTRKers ICAN international cancer advocacy network Biomarker Collaborative
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
Explore all programmes